BioXcel Therapeutics Form 144: 19,419 RSUs Vest

BioXcel Therapeutics filed a Form 144 notice relating to Common Stock.

Rhea-AI Filing Summary

BioXcel Therapeutics filed a Form 144 notice relating to Common Stock. The filing records the vesting of restricted stock unit awards of 19,419 shares on 05/04/2026. The record lists 30,877,605 shares outstanding as of 05/20/2026 and identifies NASDAQ as the exchange and Merrill Lynch as the broker location.

Insights

Securities Counsel

Form 144 documents a proposed affiliate resale after RSU vesting.

The filing records the vesting of restricted stock unit awards totaling 19,419 shares on 05/04/2026. It lists exchange and broker details and an outstanding share count of 30,877,605 shares as of 05/20/2026.

Sale mechanics and timing are not specified in the excerpt; subsequent submissions or broker instructions would provide transaction timing and proceeds details.

Key Figures

Form type: Form 144 Vested RSUs: 19,419 shares Shares outstanding: 30,877,605 shares +2 more

5 metrics

Form type Form 144 Notice of proposed sale of affiliate securities

Vested RSUs 19,419 shares Vesting of restricted stock unit awards on <date>05/04/2026</date>

Shares outstanding 30,877,605 shares Shares outstanding as of <date>05/20/2026</date>

Exchange NASDAQ Listed exchange for the Common Stock referenced

Broker location Merrill Lynch, 225 Liberty Street, New York NY Broker details shown on the form

Key Terms

restricted stock unit awards, Form 144, vesting

3 terms

restricted stock unit awards financial

"Vesting of restricted stock unit awards"

Restricted stock unit awards are company promises to deliver a specific number of shares to employees or service providers in the future once conditions—such as staying with the company for a set time or meeting performance targets—are met. They matter to investors because when the promises convert into actual shares they increase the total share count and can reduce earnings per share, while also aligning recipients’ interests with stock performance much like deferred pay that turns into ownership if goals are met.

Form 144 regulatory

"Filer Information | 144: Filer Information"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

vesting financial

"05/04/2026 | Vesting of restricted stock unit awards"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does BioXcel Therapeutics' Form 144 report show?

The Form 144 reports the vesting of 19,419 restricted stock units on 05/04/2026. It lists broker details and an exchange for potential resale.

How many shares were recorded as outstanding in the filing for BTAI?

The filing lists 30,877,605 shares outstanding as of 05/20/2026. This figure appears alongside exchange and broker information in the excerpt.

Does the Form 144 specify when the vested shares will be sold?

No specific sale timing is provided in the excerpt. The notice documents vested RSUs of 19,419 shares; sale mechanics are not shown here.

Which broker and exchange are identified in the Form 144 for BTAI?

The filing lists Merrill Lynch, 225 Liberty Street, New York as broker location and NASDAQ as the exchange for the Common Stock referenced.

Are the vested RSUs described as compensation or transfer in the filing?

The excerpt states the securities were granted as part of issuer equity compensation plan and records their vesting on 05/04/2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/20/2026 - 04:29 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001733369
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	BioXcel Therapeutics, Inc.
SEC File Number	001-38410
Address of Issuer	555 LONG WHARF DRIVE NEW HAVEN CONNECTICUT 06511
Phone	203-643-8060
Name of Person for Whose Account the Securities are To Be Sold	Mehta Vimal
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Merrill Lynch 225 Liberty Street Floor 37 New York NY 10281	19419	21113.72	30877605	05/20/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	05/04/2026	Vesting of restricted stock unit awards	BioXcel Therapeutics, Inc.			19419	05/04/2026	Granted as part of issuer equity compensation plan

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	05/20/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	02/04/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Vimal Mehta
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)